CN115137772B - Application of rose extract in preparation of medicine for preventing and treating diseases caused by premature aging of alveolar epithelial cells - Google Patents
Application of rose extract in preparation of medicine for preventing and treating diseases caused by premature aging of alveolar epithelial cells Download PDFInfo
- Publication number
- CN115137772B CN115137772B CN202210581618.6A CN202210581618A CN115137772B CN 115137772 B CN115137772 B CN 115137772B CN 202210581618 A CN202210581618 A CN 202210581618A CN 115137772 B CN115137772 B CN 115137772B
- Authority
- CN
- China
- Prior art keywords
- rose
- extract
- rose extract
- alveolar epithelial
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000220317 Rosa Species 0.000 title claims abstract description 73
- 239000000284 extract Substances 0.000 title claims abstract description 64
- 210000002821 alveolar epithelial cell Anatomy 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 16
- 201000010099 disease Diseases 0.000 title claims abstract description 14
- 206010063493 Premature ageing Diseases 0.000 title claims abstract description 12
- 208000032038 Premature aging Diseases 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 60
- 230000000694 effects Effects 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 102000005936 beta-Galactosidase Human genes 0.000 claims abstract description 16
- 108010005774 beta-Galactosidase Proteins 0.000 claims abstract description 16
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 19
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 230000032683 aging Effects 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 229930192392 Mitomycin Natural products 0.000 claims description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 7
- 229960004857 mitomycin Drugs 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 3
- 230000007935 neutral effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 38
- 230000032677 cell aging Effects 0.000 abstract description 23
- 210000002919 epithelial cell Anatomy 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000002028 premature Effects 0.000 abstract description 2
- 239000005456 alcohol based solvent Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 17
- 239000000243 solution Substances 0.000 description 13
- 210000004379 membrane Anatomy 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 239000002033 PVDF binder Substances 0.000 description 10
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 10
- 238000011534 incubation Methods 0.000 description 9
- 239000007853 buffer solution Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000009758 senescence Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 5
- LKZDFKLGDGSGEO-UJECXLDQSA-N kaempferol 3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O[C@H](CO)[C@@H](O)[C@@H]1O LKZDFKLGDGSGEO-UJECXLDQSA-N 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 4
- 108010041191 Sirtuin 1 Proteins 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241000628997 Flos Species 0.000 description 3
- 235000004789 Rosa xanthina Nutrition 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- RKWHWFONKJEUEF-GQUPQBGVSA-O cyanidin 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 RKWHWFONKJEUEF-GQUPQBGVSA-O 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- RDUAJIJVNHKTQC-UJECXLDQSA-N quercetin 3-O-beta-D-glucosyl-(1->2)-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O[C@H](CO)[C@@H](O)[C@@H]1O RDUAJIJVNHKTQC-UJECXLDQSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LKZDFKLGDGSGEO-UHFFFAOYSA-N 2',8-Di-Me ether,7-O-beta-D-glucuronoside-2',5,7,8-Tetrahydroxyflavone Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)OC(CO)C(O)C1O LKZDFKLGDGSGEO-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 240000006066 Rosa rugosa Species 0.000 description 2
- 235000000659 Rosa rugosa Nutrition 0.000 description 2
- 241000109329 Rosa xanthina Species 0.000 description 2
- RDUAJIJVNHKTQC-UHFFFAOYSA-N UNPD183040 Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)OC(CO)C(O)C1O RDUAJIJVNHKTQC-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- -1 linoleic acid, polysaccharide Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000651 myofibroblast Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- RDUAJIJVNHKTQC-CONRFQTISA-N quercetin 3-O-sophoroside Natural products OC[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)[C@@H](O)[C@H](O)[C@H]1O RDUAJIJVNHKTQC-CONRFQTISA-N 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101000577520 Chlamydomonas reinhardtii Photosystem I reaction center subunit III, chloroplastic Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 244000308760 Helichrysum petiolatum Species 0.000 description 1
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 102100039977 Regulator of chromosome condensation Human genes 0.000 description 1
- 101710150974 Regulator of chromosome condensation Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000037888 epithelial cell injury Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960003073 pirfenidone Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000008132 rose water Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of a rose extract in preparing a medicine for preventing and treating diseases caused by premature aging of alveolar epithelial cells, wherein the rose extract is a rose total extract, a water layer of the rose extract or an ethyl acetate layer of the rose extract, wherein alcohol solvents are adopted to soak rose, the obtained extract is concentrated to obtain the rose total extract, the rose total extract is diluted by adding water and then extracted by adopting ethyl acetate, and the separated water layer and ethyl acetate layer are respectively concentrated to obtain the water layer and the ethyl acetate layer of the rose extract. According to the invention, through in vitro cell experiments, the rose extract has the anti-alveolar epithelial cell aging activity, and particularly, the ethyl acetate layer of the rose extract can obviously reduce the p21 protein level and reduce the beta-galactosidase activity, so that a novel theory and technical support are provided for developing medicines for preventing and treating diseases caused by premature alveolar epithelial cell aging.
Description
Technical Field
The invention relates to the field of biological medicine, in particular to application of rose extract in preparing a medicine for preventing and treating diseases caused by premature aging of alveolar epithelial cells.
Background
Alveoli are the main sites of pulmonary gas exchange, and the alveolar surface is composed of mainly 2 cells, namely alveolar epithelial cells (alveolar EPITHELIAL CELLS, AECs) type i and type ii. AEC type ii is predominantly distributed between AEC types and at their junctions with adjacent alveolar spaces, in greater numbers than AEC type i. AEC ii can differentiate into type i cells and also complement itself by mitosis, and is therefore considered a stem cell of the alveolar epithelium covering about 5% of the alveolar surface area. AEC ii is considered to be the primary cell of alveolar epithelial cells, maintaining normal lung structural integrity, synthesizing and secreting alveolar surfactant and its related proteins, regulating epidermal active metabolism, maintaining alveolar environment, etc. Changes in alveolar epithelial cell function are believed to be associated with the occurrence of a variety of lung injuries and lung diseases. The number and function stability of the alveolar epithelial cells are of great significance for maintaining normal cells and functions of the alveoli, and premature aging of the alveolar epithelial cells can obviously influence the alveolar epithelial cells to lose tissue repair functions, so that the stem cells are exhausted and lung tissues are damaged. Thus, alveolar epithelial cell aging is critical for the progression of a variety of respiratory diseases. ( Liu Xinmin development of alveolar epithelial type II cell research, foreign medicine: respiratory system albums, 1994 (2): 88-91. )
Interstitial lung disease (INTERSTITIAL LUNG DISEASE, ILD), also known as diffuse parenchymal lung disease, is characterized by involvement of the lung interstitium, alveoli and surrounding tissues of the alveoli, with diffuse lung parenchyma, alveolar inflammation and interstitial fibrosis as the main pathological features. Patients mainly clinically manifest as dyspnea, diffuse decline of function, restrictive ventilation disorder, hypoxia, etc. Type II alveolar epithelial cells of ILD patients proliferate remarkably, so that the expression of salivary liquefied sugar chain antigens on the surface of the alveoli is increased, the alveolar epithelial cells age prematurely, and simultaneously, the vascular permeability is increased due to injury of the alveolar basement membrane. In clinic, immunosuppressants such as large-dose hormone or cyclophosphamide are used for treatment, and the traditional Chinese medicine composition has certain curative effect on partial patients, obvious side effect and lung fibrosis caused by interstitial lung diseases which cannot be effectively diagnosed. ( In Runjiang, clinical overview of interstitial lung disease, journal of clinical pulmonary science, 1999,1:1-5; wang Ranran, zhu Jian, zhang Jianglin, KL-6, free journal of military medicine, 2017,42 (4): 354-357; dan Yushan, shi Yan, progress in the treatment of interstitial lung disease, in the middle-and-outer-treatment, 2020, 20:196-198; wu Cong, liu Jian, guo Yali, wang Yuguang, research progress in the treatment of progressive fibrotic interstitial lung diseases, journal of the world's chinese and western medicine combination, 2021,16 (11): 2151-2156. )
Pulmonary fibrosis (polmonary fibrosis, PF) is a chronic progressive pulmonary interstitial disease that is caused by lung injury from a variety of causes, including early stage acute inflammatory reactions of the lower respiratory tract, including alveolar epithelial cell injury, fibroblast proliferation, inflammatory cell infiltration, etc., ultimately leading to changes in the normal pulmonary tissue architecture of the patient; clinically, lung function impairment and respiratory failure are mainly manifested. Pulmonary fibrosis is highly lethal, with overall survival rates of less than 50% for 5 years in patients with pulmonary fibrosis. It is counted that 80% of patients dying from illness annually worldwide are associated with pulmonary fibrosis. Studies have shown that pulmonary fibrosis is a multifactorial, complex disease, and that alveolar epithelial cell damage from a variety of causes is more likely to be the major factor. Myofibroblast aggregation, which is the core event of the progression of pulmonary fibrosis in which the decline of AECs repair function is associated with cellular aging, is a consequence of the decline of self repair function of alveolar epithelial cells in a sustained micro-injury environment. AECs after aging release transforming growth factor-beta (Transforming growth factor-beta, TGF-beta) through an aging-related secretory phenotype, matrix metalloproteinase 9 promote AECs to myofibroblasts transformation and increase collagen synthesis, ultimately exacerbating pulmonary fibrosis. Alveolar epithelial cell aging can lead to pulmonary fibrosis. The anti-alveolar epithelial cell aging effect has become one of the important ways to develop anti-pulmonary fibrosis drugs. The common medicines for resisting pulmonary fibrosis mainly comprise glucocorticoid, N-acetylcysteine, immunosuppressant azathioprine, cyclophosphamide, cytokines and the like, but the treatment effect is mostly not ideal, and adverse reactions are more and tolerance is easy to induce. At present, two medicines, namely pirfenidone and nidulans, are commonly used for treating pulmonary fibrosis in clinic, so that the progress of diseases can be slowed down, but the aging of alveolar epithelial cells cannot be prevented, the death rate cannot be effectively reduced, the treatment cost is high, and the prognosis of a patient suffering from pulmonary fibrosis is still poor. ( He Yuanfen, xie Tingting, min Xiangyu, yang Xinrong, zhao Yong, research progress of SIRT1 in the pathogenesis of idiopathic pulmonary fibrosis, medical review, 2021,27 (17): 3371-3375; dan Xiangan, "previous generation of pulmonary fibrosis", zhangjiang scientific and technological review, 2021,4:12-15; helichrysum, showeili, cao Yinfang, liu Jiayi, liang Zigong. IGF-1 promotes the molecular mechanisms involved in the progression of pulmonary fibrosis by aging of alveolar epithelial cells. )
Chronic obstructive pulmonary disease (chronic obstructive pulmonary disease, COPD) is a common disorder characterized by persistent airflow limitation, small airway obstruction, pulmonary elastosis degradation, alveolar structure destruction and loss, and air cavity enlargement are characteristic weapon manifestations in patients with chronic obstructive pulmonary disease, and are also key factors in progressive decline of pulmonary function. Chronic obstructive pulmonary disease has become the third most common cause of death worldwide, and there is currently no drug that can improve the long-term decline of lung function in patients with chronic obstructive pulmonary disease. There is growing evidence that lung aging is markedly accelerated in patients with chronic obstructive pulmonary disease, e.g., COPD patients progress rapidly under the induction of cigarette smoke, which is associated with the acceleration of alveolar epithelial premature aging by cigarette smoke. Premature cellular aging interrupts alveolar cell tissue repair, significantly affecting patient lung function and prognosis, and thus, alveolar epithelial cell aging plays an important role in the onset of chronic obstructive pulmonary disease, accelerates in chronic obstructive pulmonary disease patients, and promotes chronic obstructive pulmonary disease progression. Anti-alveolar epithelial cell aging has become one of the important ways of developing new drugs for treating chronic obstructive pulmonary disease .(Mercado N,Ito K,Barnes PJ,Accelerated ageing of the lung in COPD:new concepts,Thorax,2015,70(5):482-489.; Liu Yuanshun, schwann, li Yaqing, etc. SIRT1 regulates the research progress of cell aging in chronic obstructive pulmonary disease, zhejiang clinical medicine, 2017,19 (4): 776-777, 787; gu Chao, xiaoqin Feng, yingying, et al, study of the effects of SIRT1/p53 and SIRT1/FoxO3a signaling pathways in type II alveolar epithelial cell aging in COPD patients, zhejiang clinical medicine, 2020,22 (6): 787-790; wang Bingna, zhang Jingxi, progress of research on the correlation of cell senescence with chronic obstructive pulmonary disease, chinese tuberculosis and journal of breathing, 2021,44 (1): 59-63.)
Rose (Rosa rugosa Thunb.) is a plant of Rosa genus of Rosaceae family, and integrates ornamental, medicinal and edible functions. In ancient traditional Chinese medicine, rose flowers are often used for regulating qi, resolving stagnation, regulating blood, dispelling blood stasis, relieving swelling, pain and maintaining beauty and keeping young. China is the origin of the rose, the history of cultivating the rose is over two thousand years, and the main origin is Shandong Pingyin, gansu bitter water, xinjiang Hetian, yunnan Kunming, anhui and the like. The flos Rosae Rugosae has rich chemical components, contains volatile oil, and contains polyphenols, tannins, kaempferol, quercetin, guanosine, hyperin, alkaloids, linoleic acid, polysaccharide, protein, aspartic acid, glutamic acid, glycine, etc. Roses have a variety of pharmacological activities, such as: the rose extract can reduce the level of aminotransferase and glutathione by inhibiting lipid and protein oxidation in mouse organs; the rose total polyphenol can reduce spontaneous activity of mice and prolong clotting time; both the rose water extract and the ethanol extract can obviously reduce the blood sugar of mice; the rose can reduce the lipid peroxide content of liver and kidney tissues; the aqueous extract of rose can inhibit the growth of staphylococcus aureus, tubercle bacillus, typhoid bacillus and the like .(Fu M,Ng T B,Jiang Y,et al.Compounds from rose(Rosa rugosa)flowers with human immunodeficiency virus type 1 reverse transcriptase inhibitory activity.Journal of Pharmacy and Pharmacoloy,2006,58:1275-1280.; Meng Aijun. The pharmacological action of rose, journal of community medicine, 2009,7 (02): 71-72; guo Yuting, lanwei, tian Saimin, et al, xinjiang's small-branch rose hypoglycemic action and mechanism research, xinjiang university journal of medical science 2015,38 (04): 452-454; zhang Wen, wang Chao, zhang Jing, et al, research progress on edible roses, china wild plant resources, 2016,35 (03): 24-30.)
At present, no research report on the effect of rose extract on resisting alveolar epithelial cell aging exists.
Disclosure of Invention
The invention aims to solve the technical problem of providing an application of rose extract in preparing a medicine for preventing and treating diseases caused by premature aging of alveolar epithelial cells.
In order to solve the technical problems, the invention provides the following technical scheme:
the invention provides application of rose extract in preparing a medicament for preventing and treating diseases caused by premature aging of alveolar epithelial cells.
Further, the rose extract is a total rose extract, an aqueous layer of rose extract or an ethyl acetate layer of rose extract.
Further, the preparation method of the rose total extract comprises the following steps: soaking dried flos Rosae Rugosae in alcohol solvent, concentrating the extractive solution to obtain total extract (RM) of flos Rosae Rugosae.
Further, the alcohol solvent is methanol.
Further, the total rose extract is diluted by adding water, insoluble impurities are filtered out by filtering, then hydrochloric acid solution is added into the filtrate to adjust the filtrate to be acidic, then ethyl acetate is adopted for extraction, and a water layer and an ethyl acetate layer are obtained by separation.
Further, a sodium hydroxide solution was added to the separated aqueous layer to be neutral, followed by concentration treatment to obtain an aqueous layer (RM 1) of rose extract.
Further, the concentration of the sodium hydroxide solution was 1%.
Further, the separated ethyl acetate layer solution was directly concentrated under reduced pressure to obtain an ethyl acetate layer (RM 2) of rose extract.
Further, the disease includes interstitial lung disease, pulmonary fibrosis, chronic obstructive pulmonary disease.
Further, the rose extract was used to down-regulate p21 protein levels.
Further, the rose extract is used to reduce beta-galactosidase activity.
The invention has the beneficial effects that:
According to the invention, methanol, water, ethyl acetate and the like are used as solvents, different rose extracts RM, RM1 and RM2 are obtained through extraction and concentration, the anti-lung epithelial cell aging activity of the rose extracts is judged by researching the influence of the different extracts on p21 protein expression and beta-galactosidase color development, and the results show that RM, RM1 and RM2 have the anti-lung epithelial cell aging activity, wherein RM2 can obviously reduce the p21 protein level and the beta-galactosidase activity, can effectively inhibit the premature aging of alveolar epithelial cells, and further delay the progress of interstitial lung diseases, pulmonary fibrosis and chronic obstructive lung diseases. In addition, the rose can be eaten and used as a medicine, is commonly used for regulating qi, resolving depression, regulating blood, dispelling stasis, relieving swelling, pain, maintaining beauty and keeping young, has no toxic or side effect, has high safety and can be used for a long time. The invention provides new theoretical and technical support for developing medicines for preventing and treating diseases caused by premature aging of alveolar epithelial cells.
Drawings
FIG. 1 is an HPLC spectrum of a mixture of control sample quercetin-3-O-sophoroside (RA) and kaempferol-3-O-sophoroside (RB) and standard samples RA, RB;
FIG. 2 is a graph showing comparison of Western blotting detection results;
FIG. 3 is the effect of rose extracts RM, RM1, RM2 and control compound on p21 protein expression; ## P <0.01 compared to the blank (control group in the figure); ** P <0.01 compared to model group;
FIG. 4 is a chart showing the phenotype of cell senescence detected by staining for beta-galactosidase activity: a is a blank group, b is a model group, c is a cyanidin-3-O-beta-D-glucoside (RE) treatment group, D is an RM treatment group, e is an RM2 treatment group, and f is an RM1 treatment group;
FIG. 5 is a graph showing the effect of rose extracts RM, RM1, RM2 and control compound on cell senescence detected by beta-galactosidase activity staining method; ## P <0.01 compared to the blank (control group in the figure); **P<0.01,* P <0.05 compared to model group.
Detailed Description
The present invention will be further described with reference to the accompanying drawings and specific examples, which are not intended to be limiting, so that those skilled in the art will better understand the invention and practice it.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used herein in the description of the invention is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and/or" as used herein includes any and all combinations of one or more of the associated listed items.
Example 1 preparation of rose extract
The present example relates to the preparation of rose extracts RM, RM1, RM2, the specific procedure being as follows:
preparation of rose extract RM: weighing 400g of dried rose, adding 400mL of methanol for soaking overnight, combining the extracting solutions obtained by the two times of extraction, and concentrating under reduced pressure to 10mL to obtain a rose extract RM;
Preparation of rose extracts RM1, RM 2: diluting the prepared rose extract RM with water to 40mL, filtering to remove water-insoluble impurities, adding a small amount of hydrochloric acid to make the solution acidic, extracting with ethyl acetate for 3 times, 40mL of ethyl acetate each time, combining the separated water layers, dripping 1% sodium hydroxide to neutralize the water layers, and concentrating to 10mL to obtain rose extract RM1; the separated ethyl acetate layers were combined and concentrated to 10mL under reduced pressure to give rose extract RM2.
Control compound: a mixture of quercetin-3-O-sophoroside and kaempferol-3-O-sophoroside (RA/RB for short) has an HPLC spectrum shown in figure 1, and the area percentage of the chromatographic peak of RA and RB is 54:46; ellagic acid (abbreviated as RC); cyanidin-3-O-beta-D-glucoside (RE for short).
Anti-alveolar epithelial cell aging experiment
P21 is an important cell cycle regulatory protein, and plays an important role in the physiological and pathological processes of cells in the growth, differentiation, aging and death processes of the cells. The most remarkable feature of cell senescence is that cells remain metabolically active for a long period of time, but p21 protein is highly expressed because they lose their ability to react with mitogens and synthesize DNA and cannot enter S phase by being blocked in G1 phase. Furthermore, senescent cells generally become larger in volume and express β -galactosidase with high enzymatic activity at pH 6.0. The cell aging beta-galactosidase staining kit takes X-Gal as a substrate, and can generate a dark blue product under the catalysis of aging-specific beta-galactosidase, so that cells or tissues which become blue and express the beta-galactosidase can be easily observed under an optical microscope, and the cell aging degree can be judged.
Thus, the present invention determines the degree of cellular senescence by analyzing the p21 protein expression and the beta-galactosidase content in the cells.
Mitomycin is a cell cycle specific alkylating antibiotic. Clinical mitomycin has mainly the manifestations of interstitial pneumonia, non-cardiac pulmonary edema, pulmonary hemorrhage and the like, wherein the highest occurrence rate is interstitial pneumonia, and the end stage of the interstitial pneumonia is manifested as pulmonary fibrosis. Experiments prove that the mitomycin can induce the aging of the alveolar epithelial cells and can be used for examining the anti-alveolar epithelial cell aging activity of a sample .(Mitomycin induces alveolar epithelial cell senescence by down-regulating GSK3β signaling,Xiafang Xua,Xionghua Sun,Xuelei Wan,Xihua Chen,Xiaogang Jiang,Toxicology Letters,2021,352:61-69.)
(1) A549 cell culture
Culturing was performed in a medium containing FBSF% of medium at 37℃in a saturated humidity incubator with 5% of CO 2. Passage was performed until the cell density reached 90%. Old medium was discarded, cells were gently rinsed with pre-heat sterilized buffer, and cells on the medium were digested with pancreatin, requiring about 1 minute of digestion. Then, the cells were counted by centrifugation at 500rpm for 5min in a 15mL EP tube, and then diluted according to the desired concentration and transferred into a 12-well plate at a density of 6000 cells per well. After 24 hours of incubation, 150 nmol.L -1 mitomycin 2. Mu.L was added, and 1, 10, 100. Mu.g.mL -1 rose extract and 1. Mu.L control compound were added, respectively, and incubation was continued after mixing for 48 hours.
(2) Western blotting to detect the effect of different rose extracts RM, RM1, RM2 and control compound on p21 protein expression
Cell collection: pre-cooling the buffer solution in advance by using ice cubes, discarding the old cell culture medium, slightly scraping the cultured A549 cells on the culture medium in the step (1), transferring the cells into an EP tube with the volume of 1.5mL by using the pre-cooled buffer solution, centrifuging at 3500rpm for 5min, and removing the upper buffer solution. Washing the cells once by using buffer solution, repeating the steps once, and obtaining the sediment for the second time, namely the collected cells, and putting the cells together with an EP tube into ice cubes for storage.
Cell lysis: adding the lysate into the collected cells, uniformly mixing the cells and the lysate, and standing on ice to fully lyse the cells for about 30 min. After the cracking is finished, ultrasonic is carried out for 8 to 10 times by an ultrasonic crusher, and then the obtained product is placed in ice cubes for standing for 10min. And centrifuging at 13000rpm for 20min at 4deg.C, discarding the precipitate, and collecting the supernatant as whole cell lysate.
Protein concentration determination: working fluid is prepared for standby according to the BCA kit specification in advance. The working solution and the obtained cell lysate are uniformly mixed in an EP tube according to the volume ratio of 10:1, then the mixture is placed in a constant temperature box at 37 ℃ for reaction for 30min, and then the EP tube of the experimental group and the EP tube of the control group are inserted into ice for stopping the reaction. Then the concentration of the reaction solution is detected by using the Nanodrop, and the data is recorded, namely the protein concentration. According to the experimental requirements, a corresponding volume of buffer is added to the cell lysate. The metal bath was centrifuged at 13000rpm for 3min at 98 ℃. The prepared sample was stored at-80℃for further use.
And (3) electrophoresis separation: SDS-PAGE gel with corresponding concentration is prepared according to experimental requirement. And assembling the electrophoresis tank, inverting the freshly prepared buffer solution into the electrophoresis tank, and filling the inner tank. And loading the sample according to the calculated volume, and after loading, filling the outer tank with buffer solution and running electrophoresis. And (3) running at 90 volts at the beginning of electrophoresis, and adjusting the voltage to 150 volts after the sample runs out of the concentrated gel to separate the sample.
Transferring: taking out the precooled transfer membrane liquid, preparing a PVDF membrane with proper size and activating the PVDF membrane with methanol. The SDS-PAGE gel after separation was gently placed on PVDF membrane and the air bubbles between gel and membrane were gently removed, and the prepared sandwich was placed in a transfer tank and transferred at 200 volts and 300 mA for 100min. After the membrane transfer is completed, the membrane transfer tank is opened to discard SDS-PAGE gel, and PVDF membrane is taken out.
Closing the skim milk: after rinsing the PVDF film with deionized water, putting the PVDF film in fresh 5% skimmed milk, and sealing the PVDF film on a swinging bed for 1 hour. After complete sealing, the recovered milk was placed at-20 ℃ and the milk residue was washed away.
Incubation resistance: and (3) properly cutting the PVDF film, and soaking the PVDF film in a corresponding antibody box for incubation for 1-1.5 hours. And recovering the primary antibody after incubation, and storing in a refrigerator at 4 ℃.
Secondary antibody incubation: HRP-labeled goat anti-mouse IgG (H/L) at a volume ratio of 1:2000 in 5% skim milk. According to the properties of the primary antibodies, the corresponding secondary antibodies were poured into an antibody incubation box along the membrane edge and placed in a swing bed for incubation for 1 hour.
Developing: the PVDF membrane is gently clamped by forceps and soaked in the developing solution, and then the membrane is placed in a gel imager for detection. The content of the target protein p21 is determined through development, and the higher the content is, the deeper the development is, which indicates that the cell aging degree is more serious.
As shown in FIG. 2, the control samples of RA/RB and RE showed a depth of development consistent with that of the model, indicating that RA/RB and RE did not down-regulate mitomycin-induced alveolar epithelial cell senescence, whereas the development of RM, RM2, and RC groups became shallower with increasing concentration, and the development of RM1 alone with 10. Mu.g.mL -1 was shallower than that with 100. Mu.g.mL -1. FIG. 3 shows the effect of rose extracts RM, RM1, RM2 and control compounds on P21 protein expression, ## P <0.01 compared to the blank (control group in the figure); ** P <0.01 compared to model group. From the figure, samples RM, RM1, RM2 and RC can reduce the expression of p21 protein and have better anti-alveolar epithelial cell aging activity.
(3) Beta-galactosidase activity staining method for detecting influence of different rose extracts RM, RM1, RM2 and control compound on cell aging
Removing the culture solution on the culture plate in the step (1), washing once with the buffer solution, adding 1mL of beta-galactosidase staining fixative solution, standing at room temperature for 15min to fully fix the culture solution, removing the fixative solution, and washing the cells 3 times with the buffer solution for 3min each time. The buffer was then removed, 1ml of staining working solution was added to each well, and after incubation overnight at 37℃the wells were observed under a common light microscope. The higher the degree of cell senescence, the higher the beta-galactosidase content, and the more blue product is produced in the cells. And determining whether the sample has anti-aging activity by comparing the number difference of blue cells under a microscope of the sample group with that of the model group.
The results of the color development are shown in FIG. 4, and the numbers of blue cells are counted, and the results are shown in FIG. 5, wherein the RE group has the least blue cells, and the RM2 group, RM and RM1 have insignificant effect on the cells
From the experimental results, the total extract RM of the rose, the water layer RM1 of the rose extract and the ethyl acetate layer RM2 of the rose extract have certain anti-alveolar epithelial cell aging activity, and particularly the ethyl acetate layer RM2 of the rose extract has obvious anti-alveolar epithelial cell aging activity, can obviously reduce the p21 protein level and reduce the beta-galactosidase activity.
The above-described embodiments are merely preferred embodiments for fully explaining the present invention, and the scope of the present invention is not limited thereto. Equivalent substitutions and modifications will occur to those skilled in the art based on the present invention, and are intended to be within the scope of the present invention. The protection scope of the invention is subject to the claims.
Claims (3)
1. Use of rose extract in the manufacture of a medicament for the prevention and treatment of a disease caused by premature aging of alveolar epithelial cells, characterized in that the premature aging of alveolar epithelial cells is mitomycin-induced aging of alveolar epithelial cells;
the rose extract is a rose total extract, a water layer of the rose extract or an ethyl acetate layer of the rose extract;
soaking the rose in methanol, and concentrating the obtained extract to obtain the total rose extract;
Diluting the total rose extract with water, filtering to remove water-insoluble impurities, adding hydrochloric acid solution into the filtrate to adjust the filtrate to be acidic, extracting with ethyl acetate, and separating to obtain an ethyl acetate layer of the rose extract;
diluting the total rose extract with water, filtering to remove water-insoluble impurities, adding hydrochloric acid solution into the filtrate to adjust the filtrate to be acidic, extracting with ethyl acetate, adding sodium hydroxide solution into the separated water layer to be neutral, and concentrating to obtain a water layer of the rose extract;
The diseases include interstitial lung diseases, pulmonary fibrosis and chronic obstructive lung diseases.
2. The use according to claim 1, wherein the rose extract is used to down-regulate p21 protein levels.
3. The use according to claim 1, wherein the rose extract is used to reduce β -galactosidase activity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210581618.6A CN115137772B (en) | 2022-05-26 | 2022-05-26 | Application of rose extract in preparation of medicine for preventing and treating diseases caused by premature aging of alveolar epithelial cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210581618.6A CN115137772B (en) | 2022-05-26 | 2022-05-26 | Application of rose extract in preparation of medicine for preventing and treating diseases caused by premature aging of alveolar epithelial cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115137772A CN115137772A (en) | 2022-10-04 |
| CN115137772B true CN115137772B (en) | 2024-05-10 |
Family
ID=83405978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210581618.6A Active CN115137772B (en) | 2022-05-26 | 2022-05-26 | Application of rose extract in preparation of medicine for preventing and treating diseases caused by premature aging of alveolar epithelial cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115137772B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417679A (en) * | 2013-09-11 | 2013-12-04 | 河南中医学院 | Method for extracting anti-cerebral-ischemia material from roses and application of anti-cerebral ischemia material |
| CN104083476A (en) * | 2014-07-24 | 2014-10-08 | 河南中医学院 | Application of rose extract in preparing anti-depression medicaments |
| CN105663329A (en) * | 2016-03-01 | 2016-06-15 | 中国农业大学 | Comprehensive utilization method of roses |
| CN113444577A (en) * | 2020-03-25 | 2021-09-28 | 广东省禾基生物科技有限公司 | Extraction method and application of rose cell water and rose essential oil |
-
2022
- 2022-05-26 CN CN202210581618.6A patent/CN115137772B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417679A (en) * | 2013-09-11 | 2013-12-04 | 河南中医学院 | Method for extracting anti-cerebral-ischemia material from roses and application of anti-cerebral ischemia material |
| CN104083476A (en) * | 2014-07-24 | 2014-10-08 | 河南中医学院 | Application of rose extract in preparing anti-depression medicaments |
| CN105663329A (en) * | 2016-03-01 | 2016-06-15 | 中国农业大学 | Comprehensive utilization method of roses |
| CN113444577A (en) * | 2020-03-25 | 2021-09-28 | 广东省禾基生物科技有限公司 | Extraction method and application of rose cell water and rose essential oil |
Non-Patent Citations (2)
| Title |
|---|
| 玫瑰花总黄酮微波辅助提取及其抗氧化研究;周达等;《食品工业科技》;269摘要段 * |
| 过氧化氢诱导BMSCs氧化衰老模型的建立及其对相关基因p16、p21、p53表达的影响;郭柏铭等;《广州中医药大学学报》;第620页3讨论第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115137772A (en) | 2022-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Effects of asiaticoside on levels of podocyte cytoskeletal proteins and renal slit diaphragm proteins in adriamycin-induced rat nephropathy | |
| US20190269609A1 (en) | A multi-component injection | |
| CN114214363B (en) | Anti-mesenchymal stem cell aging modification method and application thereof | |
| Habib et al. | Effect of combined therapy of mesenchymal stem cells with GLP-1 receptor agonist, exenatide, on early-onset nephropathy induced in diabetic rats | |
| CN114504591B (en) | Pharmaceutical application of ganoderma lucidum tRs in asthma treatment | |
| CN115137772B (en) | Application of rose extract in preparation of medicine for preventing and treating diseases caused by premature aging of alveolar epithelial cells | |
| CN113493491A (en) | Polypeptide for preventing or treating ulcerative colitis | |
| US20230057861A1 (en) | Use of corydalis saxicola bunting and formulation thereof in preparation of drug for treating non-alcoholic fatty liver diseases | |
| KR101829209B1 (en) | Cosmetic composition with the extract of Cornus officinalis for the improvement of skin redness or face redness | |
| Sarkar et al. | Evaluation of in vitro anti diabetic activity of two mangrove plant extracts: Heritiera fomes and Sonneratia apetala | |
| CN116196334A (en) | Application of mesenchymal stem cell-derived small extracellular vesicles in preparation of drugs for treating diabetic retinopathy | |
| Chang et al. | Euonymus alatus in the treatment of diabetic nephropathy in rats | |
| CN109528744A (en) | Gentiamarin and its application | |
| CN110201025B (en) | Application of cyclocarya paliurus extract in preparation of medicine for treating or preventing diabetic cardiomyopathy | |
| CN112494487A (en) | Application of hirsutine in preparation of medicines for improving insulin resistance, diabetes and complications thereof | |
| CN114276998B (en) | Anti-aging modification method of adipose-derived mesenchymal stem cells and application thereof | |
| CN105343109A (en) | Application of cycloastragenol in preparation of drugs for protecting liver and promoting liver injury restoration | |
| CN111588772A (en) | Houttuynia cordata water decoction extract for resisting oxidative stress and preparation method and application thereof | |
| CN113101338B (en) | Decoction for treating type I diabetes mellitus and preparation method and application thereof | |
| CN115192563B (en) | Use of C3a/C3aR pathway antagonists for the treatment of primary membranous nephropathy | |
| CN113101340B (en) | Medicine for treating type I diabetes and preparation method and application thereof | |
| CN116854774B (en) | Derived peptides, telomere length modulators and their use in anti-aging | |
| CN114832025B (en) | Preparation method and application of ginseng adventitious root crude extract | |
| WO2024083176A1 (en) | Drug for treating or preventing macrophage-mediated diseases and use thereof | |
| CN107349318B (en) | Blood fat reducing pericarpium trichosanthis compound and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |